Please Wait.....
Report
Bronchitis Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
Market Report I 2023-01-23 I 112 Pages I Mordor Intelligence
The bronchitis treatment market is expected to grow at a CAGR of 3.6% over the forecast period (2022-2027).
The onset of the COVID-19 pandemic has led to a reduction in the number of patient visits that reduced the number of patients opting for bronchitis treatment, thereby impacting the market growth. For instance, as per a September 2020 published article titled, "Reduction in ambulatory visits for acute, uncomplicated bronchitis: an unintended but welcome result of the coronavirus disease 2019 (COVID-19) pandemic", the COVID-19 pandemic, while challenging for so many other aspects of antimicrobial stewardship, has led to an overall net reduction in ambulatory adults seeking care for bronchitis in the health system and has resulted in a dramatic reduction in antibiotic prescriptions for the condition. As a result, the impact of COVID-19 on the market was adverse during the initial phase of the pandemic.
Further, the major factors fueling the market's growth are the rise in the geriatric population with an augmented incidence of bronchitis, the growing prevalence of chronic obstructive pulmonary disease (COPD), an upsurge in the smoking populace, and rising levels of chemical pollutants.
The increased prevalence of COPD is a major factor driving the market growth. For instance, as per the House of Commons 2022, NHS Digital data shows that in 2020-2021, approximately 1.17 million people in England have been diagnosed with COPD, which is around 1.9% of the population. Also, as per a June 2021 update by the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Thus, the increasing burden of COPD is leading to increasing demand for bronchitis treatment, as chronic bronchitis is one of the most common conditions leading to COPD, thereby contributing to the market growth.
However, the patent expiry of key drugs is a major factor hindering the bronchitis treatment market's growth.
Bronchitis Treatment Market Trends
The Bronchodilators Segment is the Expected to Show a High Growth During the Forecast Period
By class of drugs, the bronchodilator segment is anticipated to hold a major share of the market. Bronchodilators are drugs that open the airway passages and are also used for expanding the windpipe, thus improving the breathing of individuals suffering from lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD). Bronchodilators are the first-line medication for the treatment of bronchitis for clearing the airway obstruction, which is an essential parameter in chronic bronchitis to ease the breathing in patients.
Further, the major factors, such as the increasing incidence of respiratory diseases, the rising prevalence of smoking, and the rising product approvals, are driving the growth of the market segment. Therefore, as the number of respiratory diseases is increasing, the demand for bronchodilators is all set to increase. For instance, as per a February 2022 article published by the National Center for Bio, titled "Acute Bronchitis", it is estimated that every year, 5% of the general population reports an episode of acute bronchitis, accounting for more than 10 million office visits annually. Thus, the growing burden of bronchitis is increasing the demand for bronchitis treatment, thereby contributing to the market growth.
In addition, several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, in February 2022, the United States Food and Drug Administration (USFDA) approved Lupin Limited's generic form of Brovana (arformoterol tartrate) for treating bronchoconstriction in people with chronic obstructive pulmonary disease (COPD). The active agent in Brovana is a bronchodilator, a substance that prompts the airways to relax and widen, thus lessening bronchoconstriction.
Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.
North America Dominates the Market and is Expected to do Same in the Forecast Period
Within North America, the United States has held the major share of the bronchitis treatment market.
This is due to factors such as the rising incidence of bronchitis and an increasing trend of smoking in the young generation along with an increasing number of strategic initiatives by the market players. For instance, as per a February 2022 update by the Centers for Disease Control and Prevention (CDC), 5% of the adults in the United States were diagnosed with chronic obstructive pulmonary disease (COPD), emphysema, or chronic emphysema in 2020. Thus, as COPD is associated with bronchitis, there is a significant demand for bronchitis treatment in the country, thereby contributing to the market growth.
Additionally, several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, in June 2021, Lupin launched the generic inhalation product Arformoterol to treat chronic bronchitis in the United States market. Such developments are anticipated to fuel the development of more such products and their approval for the treatment of bronchitis in the country, which will further boost the market growth in the coming period.
Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.
Bronchitis Treatment Market Competitor Analysis
The bronchitis treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy's Laboratories Ltd, Melinta Therapeutics, Sanofi SA, Boehringer Ingelheim International GmbH, and Pfizer Inc.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Geriatric Population with Increased Incidence of Bronchitis
4.2.2 Increased Prevalence of COPD Cases
4.2.3 Increased Smoking and Rising Levels of Chemical Pollutants
4.3 Market Restraints
4.3.1 High Cost and Strict Regulation for Drug Approval
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Class of Drugs
5.1.1 Antibiotics
5.1.2 Anti-inflammatory Drugs
5.1.3 Bronchodilator
5.1.4 Other Drugs
5.2 By Type
5.2.1 Acute Bronchitis
5.2.2 Chronic Bronchitis
5.3 By End User
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Other End Users
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca PLC
6.1.2 Novartis AG
6.1.3 GlaxoSmithKline PLC
6.1.4 Dr. Reddy's Laboratories Ltd
6.1.5 Sanofi SA
6.1.6 Boehringer Ingelheim International GmbH
6.1.7 Pfizer Inc.
6.1.8 Melinta Therapeutics
6.1.9 Lupin Limited
6.1.10 Cadila Healthcare Limited
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security